Comparison of morrow procedure and transapical beating-heart septal myectomy in patients with hypertrophic obstructive cardiomyopathy: a systematic review and meta-analysis

Maxat Zhakayev, Rustem Tuleutayev, Нурбай Жанар Нурбайкызы, Marina R. Izmailovich

Frontiers in Surgery, 2025

Full text Open access: Gold Metadata (CSL-JSON)
DOI 10.3389/fsurg.2025.1666236
Data confidence 70 medium
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

Introduction Transaortic surgical myectomy is the established gold-standard treatment for hypertrophic obstructive cardiomyopathy (HOCM). In contrast, the less invasive transapical beating-heart septal myectomy (TABSM) has recently gained attention as a potential alternative, although comparative evidence regarding their clinical outcomes remains limited. Objectives To compare the efficacy and safety of surgical myectomy and TABSM in patients with HOCM. Methods A systematic search of PubMed, Web of Science, Cochrane Library, and ScienceDirect (January 2014–May 2025) identified 24 observational studies including 3,732 patients (2,824 surgical myectomy; 908 TABSM). The primary outcome was the change in left ventricular outflow tract pressure gradient (LVOTPG). Secondary outcomes included improvement in NYHA class, prevalence of moderate-to-severe mitral regurgitation (MR ≥ 2), short-term (30-day) and long-term mortality, and the rate of postoperative permanent pacemaker implantation. Random-effects meta-analysis and meta-regression were performed. Results Both procedures achieved substantial and comparable reductions in LVOTG, with no significant between-group difference (p = 0.75). Functional status improved in both cohorts; younger age and higher study quality were independently associated with greater improvement in NYHA class (p < 0.05). Residual MR ≥ grade 2 decreased in both groups. 30-day mortality was low and similar between surgical myectomy and TABSM. Long-term mortality appeared lower after TABSM (≈2%) compared with surgical myectomy (≈6%); however, this finding should be interpreted cautiously due to substantial heterogeneity and shorter follow-up in TABSM studies. Pacemaker implantation occurred less frequently after TABSM than after surgical myectomy (≈2% vs. ≈6%; p = 0.03). Conclusion Both surgical myectomy and TABSM are effective and safe approaches for septal reduction in HOCM. While surgical myectomy remains the reference standard, TABSM represents a promising minimally invasive option, particularly in anatomically complex or reoperative cases. Prospective studies with standardized endpoints are required to guide individualized procedural selection and confirm long-term outcomes. Systematic Review Registration https://www.crd.york.ac.uk/PROSPERO/view/CRD420251075522 , Identifier CRD420251075522.